News >

Expert Sheds Light on Uterine Leiomyosarcoma Diagnosis, Treatment

Caroline Seymour
Published: Saturday, Dec 15, 2018

Kristen N. Ganjoo, MD

Kristen N. Ganjoo, MD

Many uterine leiomyosarcomas present as metastatic disease after having been misdiagnosed as a fibroid, explained Kristen N. Ganjoo, MD, and although there are treatment options for these patients, an early and accurate diagnosis is the only chance of cure.

“Unfortunately, it’s really hard to diagnose patients based on an ultrasound or magnetic resonance imaging. If you do a biopsy, you may biopsy a part that is nondiagnostic,” said Ganjoo, an associate professor of medicine at Stanford University Medical Center. “Usually, the main key is rapid growth in the abdomen. If a patient has an ultrasound, and then 6 months later, it has doubled in size, then it’s a uterine sarcoma.”

If a uterine leiomyosarcoma spreads into the abdomen, Ganjoo noted physicians have several chemotherapies to choose from, including the combination of gemcitabine/docetaxel and doxorubicin/olaratumab (Lartruvo).

Immunotherapy is under investigation, but it has shown modest activity when used as a single agent in this setting. A phase II study (NCT02500797) examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) demonstrated efficacy in patients with metastatic sarcoma, responses of which extended to those with uterine leiomyosarcoma, said Ganjoo.

In an interview during the 2018 OncLive® State of the Science Summit™ on Ovarian Cancer and Soft Tissue Sarcoma, Ganjoo discussed the diagnosis, presentation, and management of patients with uterine leiomyosarcoma.

OncLive: How common are uterine leiomyosarcomas?

Ganjoo: Uterine sarcomas are very rare. There are 3 main types of sarcomas found in the uterus: leiomyosarcoma—which is the most common—undifferentiated sarcoma, and endometrial stromal sarcoma. There are about 5000 cases of uterine sarcomas in the United States every year. The only treatment that can possibly cure them is surgery. Early diagnosis is extremely important. If the disease is metastatic, then it becomes incurable.

Do the majority of patients present as metastatic by the time they are given a diagnosis?

Usually, these tumors are found in younger women. Many of these women are diagnosed with fibroids, which are a benign form of smooth muscle, [also known as] leiomyomas. When they are discovered, usually there is tumor growth. The abdominal mass shows, and then there’s bleeding; at that point, it’s metastatic. Some patients who are presumed to have fibroids will undergo a procedure called morcellation, where the uterus is broken into parts and then they are suctioned out. At the end of the day, the [surgeon] discovers that it’s really a leiomyosarcoma after everything has spread in the abdomen. Of 350 patients who have a fibroid, 1 will have a leiomyosarcoma. Of those patients who have a morcellation, almost all patients [have disease that] spreads and recurs.

What treatment options are available in this space?

The treatment is surgery. If the patient has early-stage disease, we really don’t have good studies to prove that adjuvant chemotherapy helps prevent recurrence. Some phase II studies have shown some promise. The phase III study didn’t have enough accrual, so that study was abandoned. Generally, we don’t recommend chemotherapy after surgery for stage I or II disease. If it’s a larger tumor or more of an aggressive stage II disease, then we usually recommend chemotherapy to prevent metastatic lesions from growing. For patients with early-stage disease, [the options are] really just surgery and possibly radiation therapy to ensure that there is no local recurrence.

For patients who have metastatic disease, several different kinds of treatments are available. Several chemotherapies were approved over the past 5 years. For 20 to 30 years, we just had 1 chemotherapy, but now we have multiple—especially for leiomyosarcomas. We’re testing immunotherapy now. We haven’t had much luck with immunotherapy in uterine leiomyosarcomas, but that’s still a potential option.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Show Me the Data™: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian CancerJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication